Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Top Cited Papers
Open Access
- 1 September 2017
- journal article
- Published by Elsevier in Cell Reports
- Vol. 20 (13) , 3025-3033
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- NIH (2R01CA120409)
- Novartis Alliance
- NIH (T32 CA009140)
This publication has 31 references indexed in Scilit:
- Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical ApplicationJournal of Immunotherapy, 2012
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioningBlood, 2012
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy, 2009
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- Stimulatory and costimulatory effects of IL-18 directed to different small intestinal CD43 T cell subsetsJournal of Leukocyte Biology, 2007
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian CancerClinical Cancer Research, 2006